CRISPR-Cas9 Gene Editing with FluidFM®

This article covers the topic of CRISPR-Cas9 gene editing from its working principle to its applications in genome engineering. The reader can explore how this versatile tool can be employed for precision gene editing.

Go straight to:

What is CRISPR gene editing? 

In brief, it's a tool employed to alter of the genetic code

CRISPR Gene Editing - FluidFM by Cytosurge

Gene editing represents the action of modifying an organism’s genetic code. The term "CRISPR" signifies "Clustered Regularly Interspaced Short Palindromic Repeats" of genetic information that bacteria employ as part of an antiviral process [1]. Practically-speaking, CRISPR genome editing represents the actions of accurately cutting DNA and allowing natural repair mechanisms to occur.  These actions enable the addition, the removal of genetic information or even the alteration at a specific location within the genome. In the literature, multiple gene editing methods have been reported and thoroughly investigated. However, the explosion of the CRISPR-cas9 genome editing method has transformed dramatically both biomedical and life sciences research. 

Do you need more information about CRISPR gene editing?

Why is CRISPR the current best gene editing technique?

The ease with which CRISPR-Cas9 can be tuned to recognize new genomic sequences has driven a revolution in genome editing that has accelerated scientific breakthroughs and discoveries in disciplines as diverse as synthetic biology, human gene therapy, disease modeling, drug discovery, neuroscience, and the agricultural sciences. [2] Nevertheless, several difficulties remain for the current research - notably for areas where multiple simultaneous edits are required within the same cell line or organism, CRISPR-cas9 approach remains the best approach.

Time, budget and safety, are at the heart of any researcher's quest for the best genome editing method. As a matter of fact, CRISPR-Cas9 gene editing method has now certainly outstripped its predecessors in terms of ease of use and editing efficiencies. The remaining challenge for CRISPR-Cas9 gene editing is now to find innovative ways to get around delivery limitations.

Illustration of CRISPR-Cas9 Gene editing 

What is FluidFM® CRISPR genome editing used for?

CRISPR-Cas9 Gene Editing with FluidFM®

An example of a CRISPR-Cas9 Genome Editing Tool: the FluidFM® 

Cytosurge employs its proprietary patented technology - the FluidFM technology - to offer a unique gene editing tool - the FluidFM OMNIUM. The FluidFM technology offers a unique in-vitro solution to improve the efficiency and applicability of CRISPR across a variety of cell types and for cell line development. Seven decades ago, the complex evolution of genome engineering started with the discovery of the DNA double helix. Throughout the years, researchers uncovered different tools to perfect gene editing. The FluidFM OMNIUM illustrates today's best supporting tool to perform high-efficiency precision genome engineering.

Biological research

Gene and cell therapy


Agriculture & Plant Biotechnology

Benefits and features of the FluidFM® CRISPR Gene Editing

Direct intra-nuclear Injection

Reach an unprecedented precision delivery and a high CRISPR HDR efficiency due to a ultra-gentle transfection method based on nano-injection.

High Cell Viability

The gentle injection or extraction ensure your cell viability. Especially suitable for hard-to-transfect cells and rare cell types.  

Continuous Cell Monitoring

Easily introduce multiple gene edits in one go while maintaining your cells alive. Fasten your stable monoclonal cell lines generation!

Do you want full control over your CRISPR gene editing? 

Example n*1: Multiplex CRISPR editing and monoclonal cell line development with the FluidFM® 

FluidFM nano-injection overcomes delivery limitations of current CRISPR gene editing methods, accelerates cell line development cycles, and is poised to significantly broaden multiplexing capabilities. Pharmaceutical and biological research as well as biologics manufacturing rely on genetically modified cell lines with genes that have been modified to induce the desired phenotype. With the discovery and development of gene editing technologies like CRISPR, the potential of doing multi-loci edits has received much interest but has proven to be a tedious and long process. In the following, we demonstrate the generation of a monoclonal multiple Knock-Out cell line in less than three weeks with the help of the FluidFM technology.

Do you want an unlimited access to reliable and reproducible cell lines

Why choosing the FluidFM CRISPR gene editing?

Being researchers ourselves, our team has identified over the years and the research projects, two main needs for CRISPR-Cas9 gene editing tool in the research community:

  • The versatility, accuracy and ease of use of a CRISPR gene editing tool - the FluidFM OMNIUM - that allows you to perform as many gene edition as you want (KO, KI) while maintaining your cells alive and well! 

  • The precision, reliability and reproducibility of a CRISPR-cas9 cell line development service: Focus on your science, we take care of the rest! 

Are you still unsure if the FluidFM CRISPR-cas9 gene editing suits your application? 

Contact our team of experts to find the right solution for your research project.

Conclusions - Take Away Message

CRISPR Gene Editing

Currently, the most versatile gene editing method available on the market.

The FluidFM Technology

The only CRISPR gene editing supporting technology which provides direct single-cell intra-nuclear injection, extraction or manipulation with a high HDR efficiency  

Versatile Cell Engineering

Full control gene editing OR reliable and reproducible monoclonal cell lines? Everything is possible with the FluidFM Technology!


[1] Jinek, Martin, et al. "A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity." science 337.6096 (2012): 816-821.

[2] Li, Hongyi, et al. "Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects." Signal transduction and targeted therapy 5.1 (2020): 1-23.